Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPI-386 Nasal Gel for Motion Sickness
NCT05548270Phase 3Completed
- Sponsor
- Defender Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Placebo
- Countries
- 1
01
Overview
A Phase 3 trial of placebo gel (Naval Aeromedical Research Unit, Dayton) in motion sickness, sponsored by Defender Pharmaceuticals. Started Aug 2022; status: completed.
02
Drugs
placebo gel (Naval Aeromedical Research Unit, Dayton)
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT05548270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05548270.